View Financial HealthRemeGen 配当と自社株買い配当金 基準チェック /06RemeGen配当金を支払った記録がありません。主要情報n/a配当利回り-1.2%バイバック利回り総株主利回り-1.2%将来の配当利回り0%配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Jun 30RemeGen Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026RemeGen Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €8.87, the stock trades at a forward P/E ratio of 15x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 124% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.10 per share.New Risk • Jun 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. High level of non-cash earnings (36% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).お知らせ • Jun 09+ 3 more updatesRemegen Co., Ltd. Receives Nmpa Approval for New Indication of Telitacicept for Injection for Treatment of Sjögren’S SyndromeRemeGen Co., Ltd. has received the Drug Registration Certificate approved and issued by the National Medical Products Administration. The new indication of Telitacicept for Injection (code: RC18, brand name: ??®, approval number: National Medicine Approval S20210008, certificate number: 2026S01909) for the treatment of Sjögren’s syndrome (Sjögren’s disease) has been approved for marketing. Pursuant to the Drug Administration Law of the People’s Republic of China and relevant regulations, upon review, Telitacicept for Injection complies with the relevant requirements for drug registration. The marketing of this product for the new indication of active Sjögren’s syndrome (Sjögren’s disease) (ESSDAI = 5) on the basis of conventional therapy in adult patients is approved. Telitacicept is a BLyS/APRIL dual-targeting innovative drug independently developed by the Company, and it is the world’s first such molecule. BLyS (B-lymphocyte stimulator) and APRIL (a proliferation-inducing ligand) are key cytokines that promote B cell survival, differentiation, and maturation. In patients with Sjögren’s disease, serum levels of BLyS and APRIL are significantly elevated, leading to B cell abnormalities and immune system disorders. By simultaneously inhibiting the binding of BLyS and APRIL to B cell surface receptors, the Telitacicept blocks abnormal B cell differentiation and maturation, thereby exerting therapeutic effects. Sjögren’s syndrome is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, resulting in progressive loss of glandular secretion. In severe cases, it may involve extra-glandular organs and cause systemic damage. In 2023, a consensus conference on the nomenclature of Sjögren’s syndrome was held in Rome, where it was agreed to rename Sjögren’s syndrome (SS) as Sjögren’s disease (SjD). SjD is a global disease with a prevalence of 0.3% to 0.7% in the Chinese population, affecting approximately 4,200,000 to 9,800,000 patients. The approval of this new indication is based on a nationwide multi-center, randomized, double-blind, placebo-controlled Phase III confirmatory clinical study, which is the first global dual-target biologic project for SjD that has successfully completed a Phase III trial and achieved strong positive results. The study demonstrated statistically significant reductions in ESSDAI score at week 24 in both the Telitacicept 160 mg and 80 mg groups compared with placebo, with efficacy persisting through week 48. The approval of this new indication has further enhanced the market competitiveness of Telitacicept. Due to the characteristics of the pharmaceutical industry, the commercialization of the drugs after marketing approval is subject to various factors including policy environment, market demand and competitive landscape, which entail certain uncertainties. The Company will fulfill its information disclosure obligations in a timely manner in accordance with subsequent developments. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.Valuation Update With 7 Day Price Move • Jun 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €7.64, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 103% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.58 per share.Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Guobin Huang was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • May 21RemeGen Co., Ltd., Annual General Meeting, Jun 16, 2026RemeGen Co., Ltd., Annual General Meeting, Jun 16, 2026, at 14:00 China Standard Time. Location: room 6134, phase iii building of the company at, 58 middle beijing road, yantai development zone, yantai area of shandong pilot free trade zone, Chinaお知らせ • Mar 30RemeGen Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026RemeGen Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026お知らせ • Jan 30RemeGen Co., Ltd. Provides Preliminary Earnings Guidance for the Year Ended December 31, 2025RemeGen Co., Ltd. provided preliminary earnings guidance for the year ended December 31, 2025. For the period, the company's operating revenue is estimated to be approximately RMB 3,250 million, representing an increase of approximately RMB 1,533.14 million in revenue as compared with the same period of last year and a year-on-year increase of approximately 89%. The Company estimates that the net profit attributable to owners of the parent company for the year of 2025 will be approximately RMB 716 million, representing a turnaround as compared with the same period of last year.決済の安定と成長配当データの取得安定した配当: REGの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: REGの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場RemeGen 配当利回り対市場REG 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (REG)n/a市場下位25% (DE)1.5%市場トップ25% (DE)4.7%業界平均 (Biotechs)2.3%アナリスト予想 (REG) (最長3年)0%注目すべき配当: REGは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: REGは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: REGの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: REGが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YDE 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/06 04:16終値2026/07/06 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋RemeGen Co., Ltd. 13 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。29 アナリスト機関Zhishun SiuCCB International Securities LimitedShun Kei LawCCB International Securities LimitedJin ZhangChina International Capital Corporation Limited26 その他のアナリストを表示
お知らせ • Jun 30RemeGen Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026RemeGen Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026
Valuation Update With 7 Day Price Move • Jun 29Investor sentiment improves as stock rises 24%After last week's 24% share price gain to €8.87, the stock trades at a forward P/E ratio of 15x. Average trailing P/E is 16x in the Biotechs industry in Europe. Total returns to shareholders of 124% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €13.10 per share.
New Risk • Jun 14New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 2.0% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 2.0% per year for the foreseeable future. High level of non-cash earnings (36% accrual ratio). Minor Risk Share price has been volatile over the past 3 months (9.7% average weekly change).
お知らせ • Jun 09+ 3 more updatesRemegen Co., Ltd. Receives Nmpa Approval for New Indication of Telitacicept for Injection for Treatment of Sjögren’S SyndromeRemeGen Co., Ltd. has received the Drug Registration Certificate approved and issued by the National Medical Products Administration. The new indication of Telitacicept for Injection (code: RC18, brand name: ??®, approval number: National Medicine Approval S20210008, certificate number: 2026S01909) for the treatment of Sjögren’s syndrome (Sjögren’s disease) has been approved for marketing. Pursuant to the Drug Administration Law of the People’s Republic of China and relevant regulations, upon review, Telitacicept for Injection complies with the relevant requirements for drug registration. The marketing of this product for the new indication of active Sjögren’s syndrome (Sjögren’s disease) (ESSDAI = 5) on the basis of conventional therapy in adult patients is approved. Telitacicept is a BLyS/APRIL dual-targeting innovative drug independently developed by the Company, and it is the world’s first such molecule. BLyS (B-lymphocyte stimulator) and APRIL (a proliferation-inducing ligand) are key cytokines that promote B cell survival, differentiation, and maturation. In patients with Sjögren’s disease, serum levels of BLyS and APRIL are significantly elevated, leading to B cell abnormalities and immune system disorders. By simultaneously inhibiting the binding of BLyS and APRIL to B cell surface receptors, the Telitacicept blocks abnormal B cell differentiation and maturation, thereby exerting therapeutic effects. Sjögren’s syndrome is a chronic autoimmune disease characterized by lymphocytic infiltration of exocrine glands, resulting in progressive loss of glandular secretion. In severe cases, it may involve extra-glandular organs and cause systemic damage. In 2023, a consensus conference on the nomenclature of Sjögren’s syndrome was held in Rome, where it was agreed to rename Sjögren’s syndrome (SS) as Sjögren’s disease (SjD). SjD is a global disease with a prevalence of 0.3% to 0.7% in the Chinese population, affecting approximately 4,200,000 to 9,800,000 patients. The approval of this new indication is based on a nationwide multi-center, randomized, double-blind, placebo-controlled Phase III confirmatory clinical study, which is the first global dual-target biologic project for SjD that has successfully completed a Phase III trial and achieved strong positive results. The study demonstrated statistically significant reductions in ESSDAI score at week 24 in both the Telitacicept 160 mg and 80 mg groups compared with placebo, with efficacy persisting through week 48. The approval of this new indication has further enhanced the market competitiveness of Telitacicept. Due to the characteristics of the pharmaceutical industry, the commercialization of the drugs after marketing approval is subject to various factors including policy environment, market demand and competitive landscape, which entail certain uncertainties. The Company will fulfill its information disclosure obligations in a timely manner in accordance with subsequent developments. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.
Valuation Update With 7 Day Price Move • Jun 06Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to €7.64, the stock trades at a forward P/E ratio of 13x. Average trailing P/E is 17x in the Biotechs industry in Europe. Total returns to shareholders of 103% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at €14.58 per share.
Board Change • May 21Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Non-Executive Director Guobin Huang was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • May 21RemeGen Co., Ltd., Annual General Meeting, Jun 16, 2026RemeGen Co., Ltd., Annual General Meeting, Jun 16, 2026, at 14:00 China Standard Time. Location: room 6134, phase iii building of the company at, 58 middle beijing road, yantai development zone, yantai area of shandong pilot free trade zone, China
お知らせ • Mar 30RemeGen Co., Ltd. to Report Q1, 2026 Results on Apr 29, 2026RemeGen Co., Ltd. announced that they will report Q1, 2026 results on Apr 29, 2026
お知らせ • Jan 30RemeGen Co., Ltd. Provides Preliminary Earnings Guidance for the Year Ended December 31, 2025RemeGen Co., Ltd. provided preliminary earnings guidance for the year ended December 31, 2025. For the period, the company's operating revenue is estimated to be approximately RMB 3,250 million, representing an increase of approximately RMB 1,533.14 million in revenue as compared with the same period of last year and a year-on-year increase of approximately 89%. The Company estimates that the net profit attributable to owners of the parent company for the year of 2025 will be approximately RMB 716 million, representing a turnaround as compared with the same period of last year.